Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Hepatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Optimising Hepatitis B Prophylaxis After Liver Transplantation
5
Mins
April 2026
Despite combination prophylaxis with HBIG and NUCs transforming outcomes after liver transplantation for hepatitis B, some studies have…
Read more
14
Mins
3 Feb 2022
Optimising Cholangiocarcinoma Diagnosis and Treatment Focusing on Precision Medicine
This article is based on interviews conducted with Lorenza Rimassa, Arndt Vogel, and Harpreet Wasan. They provided their expert opinion…
6
Mins
13 Jan 2022
New Data on Aramchol™: Efficacy of a Higher Daily Exposure to Aramchol on Fibrosis Improvement in the ARMOR Study Open-Label Part
Non-alcoholic steatohepatitis (NASH) is the advanced form of non-alcoholic fatty liver disease, which can lead to further…
12
Mins
21 Sep 2021
Using Innovation to Develop Digital Tools for Public Health During the COVID-19 Pandemic
This paper describes a case study of the co-design and development of two new COVID-19 digital services to support the Scottish…
8
Mins
21 Sep 2021
Liver Transplantation in Patients with Acute-on-Chronic Liver Failure: Challenging the Limits
The natural history of patients with cirrhosis is characterised by the development of acute decompensating events…
12
Mins
21 Sep 2021
Hepatic Manifestations of Lysosomal Storage Disorders: Differential Diagnosis, Investigations, and Treatment, Current and Upcoming
Hepatomegaly can be a presenting or associated feature of an inherited lysosomal storage disorder. Thus, a high index of suspicion should be maintained in patients without an aetiologic diagnosis. Read more.
14
Mins
21 Sep 2021
Portal Hypertension in Non-alcoholic Fatty Liver Disease in the Era of Non-invasive Assessment
Non-alcoholic fatty liver disease (NAFLD) is considered as one of the fastest emerging global health priorities due to the continuous…
6
Mins
21 Sep 2021
Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use
The benefits of rifaximin use continues to gather momentum, given its well-tolerated side-effect profile, and these require consideration.
2
Mins
5 Aug 2021
Interview: Philip Newsome
I think the underlying ethos of the ILC is that we want to bring together people who have an interest in improving the outcome of patients with liver disease…
Loading posts...
« Previous
1
…
4
5
6
7
8
…
19
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View